Gong Jingwen, Wang Qing, Chen Xing, Lu Junhui
The First Clinical Medical College, Shanxi Medical University, Taiyuan 030001, China.
Department of Gastroenterology, The First Hospital of Shanxi Medical University, Taiyuan 030001, China.
Vaccines (Basel). 2025 May 15;13(5):526. doi: 10.3390/vaccines13050526.
is a gram-negative, spiral-shaped bacterium that colonizes the human gastric mucosa, leading to various gastric diseases. infection has become a pressing public health issue that affects more than 50% of the human population worldwide, almost 40 years after its discovery. Traditional treatments, based on the use of bismuth-based triple and quadruple therapies, are effective while facing a series of problems, such as difficulty in patient compliance, the rise of antibiotic resistance, and possible recurrence of infection. Therefore, the development of an efficacious vaccine against would be extremely urgent. This review mainly elaborates on the pathogenic mechanism and immune evasion mechanism of , as well as various strategies adopted in vaccine development, including whole-cell vaccines, subunit vaccines, DNA vaccines, and live vector vaccines. Animal studies and clinical trials demonstrate that vaccines significantly reduce bacterial load and provide cellular immunity over some time. Multiple studies have clarified the advantages and limitations of each candidate vaccine. Although the development of vaccines provides benefits to reduce the global burden, there are still significant challenges to developing vaccines in safety, efficacy, and availability. Overcoming these challenges, along with the advancement of vaccine technology, can better prevent and treat infection.
是一种革兰氏阴性螺旋形细菌,可定殖于人类胃黏膜,导致各种胃部疾病。幽门螺杆菌感染已成为一个紧迫的公共卫生问题,自其发现近40年后,全球超过50%的人口受到影响。基于铋剂三联和四联疗法的传统治疗方法虽有效,但面临一系列问题,如患者依从性差、抗生素耐药性上升以及感染可能复发等。因此,开发一种有效的抗幽门螺杆菌疫苗极为迫切。本综述主要阐述幽门螺杆菌的致病机制和免疫逃逸机制,以及疫苗开发中采用的各种策略,包括全细胞疫苗、亚单位疫苗、DNA疫苗和活载体疫苗。动物研究和临床试验表明,幽门螺杆菌疫苗可显著降低细菌载量,并在一段时间内提供细胞免疫。多项研究阐明了每种候选疫苗的优缺点。尽管幽门螺杆菌疫苗的开发有助于减轻全球负担,但在安全性、有效性和可及性方面开发疫苗仍面临重大挑战。克服这些挑战,随着疫苗技术的进步,能够更好地预防和治疗幽门螺杆菌感染。